{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T09:47:44Z","timestamp":1762249664198},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,3,12]],"date-time":"2019-03-12T00:00:00Z","timestamp":1552348800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1038\/s41440-019-0239-1","type":"journal-article","created":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T15:44:35Z","timestamp":1552578275000},"page":"1125-1141","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Reversal of cardiac, vascular, and renal dysfunction by non-quinazoline \u03b11-adrenolytics in DOCA-salt hypertensive rats: a comparison with prazosin, a quinazoline-based \u03b11-adrenoceptor antagonist"],"prefix":"10.1038","volume":"42","author":[{"given":"Monika","family":"Kubacka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Zadro\u017cna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Kota\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Filipek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Maria","family":"Waszkielewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henryk","family":"Marona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Szczepan","family":"Mogilski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,12]]},"reference":[{"key":"239_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.numecd.2005.04.005","volume":"16","author":"AC Pessina","year":"2006","unstructured":"Pessina AC, Ciccariello L, Perrone F, Stoico V, Gussoni G, Scotti A, et al. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism. Nutr Metab Cardiovasc Dis. 2006;16:137\u201347.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"239_CR2","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s11906-017-0731-4","volume":"19","author":"T Basting","year":"2017","unstructured":"Basting T, Lazartigues E. DOCA-salt hypertension: an update. Curr Hypertens Rep. 2017;19:32.","journal-title":"Curr Hypertens Rep"},{"key":"239_CR3","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1097\/HJH.0b013e32833b912c","volume":"28","author":"N Chapman","year":"2010","unstructured":"Chapman N, Chen CY, Fujita T, Hobbs FD, Kim SJ, Staessen JA, et al. Time to re-appraise the role of alpha-1 adrenoceptor antagonists in the management of hypertension? J Hypertens. 2010;28:1796\u2013803.","journal-title":"J Hypertens"},{"key":"239_CR4","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.cardiores.2006.03.014","volume":"71","author":"S Eiras","year":"2006","unstructured":"Eiras S, Fern\u00e1ndez P, Pi\u00f1eiro R, Iglesias MJ, Gonz\u00e1lez-Juanatey JR, Lago F. Doxazosin induces activation of GADD153 and cleavage of focal adhesion kinase in cardiomyocytes en route to apoptosis. Cardiovasc Res. 2006;71:118\u201328.","journal-title":"Cardiovasc Res"},{"key":"239_CR5","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1161\/CIRCULATIONAHA.107.737957","volume":"118","author":"N Chapman","year":"2008","unstructured":"Chapman N, Chang CL, Dahl\u00f6f B, Sever PS, Wedel H, Poulter NR.ASCOT Investigators. Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian cardiac outcomes trial. Circulation. 2008;118:42\u20138.","journal-title":"Circulation"},{"key":"239_CR6","first-page":"495","volume":"20","author":"X Qian","year":"2016","unstructured":"Qian X, Li M, Wagner MB, Chen G, Song X. Doxazosin stimulates galectin-3 expression and collagen synthesis in HL-1 cardiomyocytes independent of protein kinase C pathway. Front Pharmacol. 2016;20:495.","journal-title":"Front Pharmacol"},{"key":"239_CR7","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s00210-009-0462-4","volume":"380","author":"N Kyprianou","year":"2009","unstructured":"Kyprianou N, Vaughan TB, Michel MC. Apoptosis induction by doxazosin and other quinazoline alpha1-adrenoceptor antagonists: a new mechanism for cancer treatment? Naunyn Schmiede Arch Pharmacol. 2009;380:473\u20137.","journal-title":"Naunyn Schmiede Arch Pharmacol"},{"key":"239_CR8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/pros.10357","volume":"59","author":"A Tahmatzopoulos","year":"2004","unstructured":"Tahmatzopoulos A, Kyprianou N. Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality? Prostate. 2004;59:91\u2013100.","journal-title":"Prostate"},{"key":"239_CR9","first-page":"4695","volume":"33","author":"J Bilbro","year":"2013","unstructured":"Bilbro J, Mart M, Kyprianou N. Therapeutic value of quinazoline-based compounds in prostate cancer. Anticancer Res. 2013;33:4695\u2013700.","journal-title":"Anticancer Res"},{"key":"239_CR10","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1161\/01.CIR.0000043803.20822.D1","volume":"107","author":"JR Gonz\u00e1lez-Juanatey","year":"2003","unstructured":"Gonz\u00e1lez-Juanatey JR, Iglesias MJ, Alcaide C, Pi\u00f1eiro R, Lago F. Doxazosin induces apoptosis in cardiomyocytes cultured in vitro by a mechanism that is independent of alpha1-adrenergic blockade. Circulation. 2003;107:127\u201331.","journal-title":"Circulation"},{"key":"239_CR11","first-page":"733","volume":"66","author":"H Marona","year":"2011","unstructured":"Marona H, Kubacka M, Filipek B, Siwek A, Dyba\u0142a M, Szneler E, et al. Synthesis, alpha-adrenoceptors affinity and alpha 1-adrenoceptor antagonistic properties of some 1,4-substituted piperazine derivatives. Pharmazie. 2011;66:733\u20139.","journal-title":"Pharmazie"},{"key":"239_CR12","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ejphar.2012.10.025","volume":"698","author":"M Kubacka","year":"2013","unstructured":"Kubacka M, Mogilski S, Filipek B, Marona H. The hypotensive activity and alpha1-adrenoceptor antagonistic properties of some aroxyalkyl derivatives of 2-methoxyphenylpiperazine. Eur J Pharmacol. 2013;698:335\u201344.","journal-title":"Eur J Pharmacol"},{"key":"239_CR13","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.biopha.2018.04.034","volume":"103","author":"M Kubacka","year":"2018","unstructured":"Kubacka M, Kota\u0144ska M, Kazek G, Waszkielewicz AM, Marona H, Filipek B, et al. Involvement of the NO\/sGC\/cGMP\/K\u2009+\u2009channels pathway in vascular relaxation evoked by two non-quinazoline \u03b11-adrenoceptor antagonists. Biomed Pharmacother. 2018;103:157\u201366.","journal-title":"Biomed Pharmacother"},{"key":"239_CR14","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1093\/ndt\/gfp604","volume":"25","author":"EH Bae","year":"2010","unstructured":"Bae EH, Kim IJ, Park JW, Ma SK, Lee JU, Kim SW. Renoprotective effect of rosuvastatin in DOCA-salt hypertensive rats. Nephrol Dial Transplant. 2010;25:1051\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"239_CR15","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2174\/157340310793566109","volume":"6","author":"A Iyer","year":"2010","unstructured":"Iyer A, Chan V, Brown L. The DOCA-salt hypertensive rat as a model of cardiovascular oxidative and inflammatory stress. Curr Cardiol Rev. 2010;6:291\u20137.","journal-title":"Curr Cardiol Rev"},{"key":"239_CR16","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.pbb.2012.03.029","volume":"102","author":"B Sharma","year":"2012","unstructured":"Sharma B, Singh N. Experimental hypertension induced vascular dementia: pharmacological, biochemical and behavioral recuperation by angiotensin receptor blocker and acetylcholinesterase inhibitor. Pharmacol Biochem Behav. 2012;102:101\u20138.","journal-title":"Pharmacol Biochem Behav"},{"key":"239_CR17","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ejphar.2008.06.073","volume":"591","author":"M Dudek","year":"2008","unstructured":"Dudek M, Bednarski M, Bilska A, Iciek M, Soko\u0142owska-Jezewicz M, Filipek B, et al. The role of lipoic acid in prevention of nitroglycerin tolerance. Eur J Pharmacol. 2008;591:203\u201310.","journal-title":"Eur J Pharmacol"},{"key":"239_CR18","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/0003-2697(68)90092-4","volume":"25","author":"J Sedlak","year":"1968","unstructured":"Sedlak J, Lindsay RH. Estimation of total, protein-bound and non-protein sulfhydryl groups in tissue with Ellman\u2019s reagent. Anal Biochem. 1968;25:192\u2013205.","journal-title":"Anal Biochem"},{"key":"239_CR19","first-page":"53","volume":"5","author":"P Guillaume","year":"2009","unstructured":"Guillaume P, Provost D, Legrand P, Godes M, Lacroix P. Models of cardiovascular disease: measurement of antihypertensive activity in the conscious rat (SHR, DOCA-salt, and Goldblatt hypertension models). Curr Protoc Pharmacol. 2009;5:53.","journal-title":"Curr Protoc Pharmacol"},{"key":"239_CR20","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/hr.2010.279","volume":"34","author":"H Toba","year":"2011","unstructured":"Toba H, Yoshida M, Tojo C, Nakano A, Oshima Y, Kojima Y, et al. L\/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in deoxycorticosterone acetate-salt hypertensive rats. Hypertens Res. 2011;34:521\u20139.","journal-title":"Hypertens Res"},{"key":"239_CR21","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1161\/01.HYP.0000185689.65045.4c","volume":"46","author":"S Perlini","year":"2005","unstructured":"Perlini S, Palladini G, Ferrero I, Tozzi R, Fallarini S, Facoetti A, et al. Sympathectomy or doxazosin, but not propranolol, blunt myocardial interstitial fibrosis in pressure-overload hypertrophy. Hypertension. 2005;46:1213\u20138.","journal-title":"Hypertension"},{"key":"239_CR22","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.pbb.2015.11.013","volume":"141","author":"M Kubacka","year":"2016","unstructured":"Kubacka M, Mogilski S, Bednarski M, Nowi\u0144ski L, Dudek M, \u017bmudzka E, et al. Antidepressant-like activity of aroxyalkyl derivatives of 2-methoxyphenylpiperazine and evidence for the involvement of serotonin receptor subtypes in their mechanism of action. Pharmacol Biochem Behav. 2016;141:28\u201341.","journal-title":"Pharmacol Biochem Behav"},{"key":"239_CR23","doi-asserted-by":"publisher","first-page":"929","DOI":"10.2165\/00003495-199856050-00016","volume":"56","author":"M Dooley","year":"1998","unstructured":"Dooley M, Goa KL. Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998;56:929\u201355.","journal-title":"Drugs"},{"key":"239_CR24","doi-asserted-by":"publisher","first-page":"7D","DOI":"10.1016\/0002-9149(89)90688-7","volume":"64","author":"N Kolassa","year":"1989","unstructured":"Kolassa N, Beller KD, Sanders KH. Involvement of brain 5-HT1A receptors in the hypotensive response to urapidil. Am J Cardiol. 1989;64:7D\u201310D.","journal-title":"Am J Cardiol"},{"issue":"Suppl. 4","key":"239_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003495-199000404-00003","volume":"40","author":"PA Zwieten Van","year":"1990","unstructured":"Van Zwieten PA, Blauw GJ, van Brummelen P. Pharmacological profile of antihypertensive drugs with serotonin receptor and alpha-adrenoceptor activity. Drugs. 1990;40(Suppl. 4):1\u20138.","journal-title":"Drugs"},{"key":"239_CR26","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.pharep.2016.05.004","volume":"68","author":"H Gandhi","year":"2016","unstructured":"Gandhi H, Naik P, Agrawal N, Yadav M. Protective effects of MCR-1329, a dual \u03b11 and angII receptor antagonist, in mineralocorticoid-induced hypertension. Pharmacol Rep. 2016;68:952\u20139.","journal-title":"Pharmacol Rep"},{"key":"239_CR27","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1159\/000343414","volume":"36","author":"EH Bae","year":"2012","unstructured":"Bae EH, Kim IJ, Joo SY, Kim EY, Kim CS, Choi JS, et al. Renoprotective effects of sildenafil in DOCA-salt hypertensive rats. Kidney Blood Press Res. 2012;36:248\u201357.","journal-title":"Kidney Blood Press Res"},{"key":"239_CR28","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1093\/ndt\/gfl230","volume":"21","author":"IZ Pawluczyk","year":"2006","unstructured":"Pawluczyk IZ, Patel SR, Harris KP. The role of the alpha-1 adrenoceptor in modulating human mesangial cell matrix production. Nephrol Dial Transplant. 2006;21:2417\u201324.","journal-title":"Nephrol Dial Transplant"},{"key":"239_CR29","first-page":"365","volume":"9","author":"DA Chistiakov","year":"2015","unstructured":"Chistiakov DA, Orekhov AN, Bobryshev YV. Endothelial barrier and its abnormalities in cardiovascular disease. Front Physiol. 2015;9:365.","journal-title":"Front Physiol"},{"key":"239_CR30","doi-asserted-by":"publisher","first-page":"H499","DOI":"10.1152\/ajpheart.00325.2011","volume":"302","author":"T Hirase","year":"2012","unstructured":"Hirase T, Node K. Endothelial dysfunction as a cellular mechanism for vascular failure. Am J Physiol Heart Circ Physiol. 2012;302:H499\u2013H505.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"239_CR31","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/ejhf.497","volume":"18","author":"JM Maaten Ter","year":"2016","unstructured":"Ter Maaten JM, Damman K, Verhaar MC, Paulus WJ, Duncker DJ, Cheng C, et al. Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation. Eur J Heart Fail. 2016;18:588\u201398.","journal-title":"Eur J Heart Fail"},{"key":"239_CR32","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1161\/CIRCULATIONAHA.107.748236","volume":"117","author":"YH Du","year":"2008","unstructured":"Du YH, Guan YY, Alp NJ, Channon KM, Chen AF. Endothelium-specific GTP cyclohydrolase I overexpression attenuates blood pressure progression in salt-sensitive low-renin hypertension. Circulation. 2008;117:1045\u201354.","journal-title":"Circulation"},{"key":"239_CR33","doi-asserted-by":"publisher","first-page":"406960","DOI":"10.1155\/2014\/406960","volume":"2014","author":"QN Dinh","year":"2014","unstructured":"Dinh QN, Drummond GR, Sobey CG, Chrissobolis S. Roles of inflammation, oxidative stress, and vascular dysfunction in hypertension. Biomed Res Int. 2014;2014:406960.","journal-title":"Biomed Res Int"},{"key":"239_CR34","doi-asserted-by":"publisher","first-page":"672","DOI":"10.2174\/1573406410666140318111328","volume":"10","author":"D Tsounis","year":"2014","unstructured":"Tsounis D, Bouras G, Giannopoulos G, Papadimitriou C, Alexopoulos D, Deftereos S. Inflammation markers in essential hypertension. Med Chem. 2014;10:672\u201381.","journal-title":"Med Chem"},{"key":"239_CR35","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.biopha.2011.09.006","volume":"66","author":"ZY Lin","year":"2012","unstructured":"Lin ZY, Chuang WL. High therapeutic concentration of prazosin up-regulates angiogenic IL6 and CCL2 genes in hepatocellular carcinoma cells. Biomed Pharmacother. 2012;66:583\u20136.","journal-title":"Biomed Pharmacother"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41440-019-0239-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41440-019-0239-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41440-019-0239-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:20:29Z","timestamp":1684617629000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-019-0239-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,12]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["239"],"URL":"https:\/\/doi.org\/10.1038\/s41440-019-0239-1","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,12]]},"assertion":[{"value":"23 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors report a grant from the National Science Centre in Poland, received during the performance of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}